AI search tool helps physicians to find the perfect clinical trials for their patients
A newly developed search tool uses AI to understand patient needs and reccomend the best clinical trials for their treatment, whilst keeping physicians centered in the process to ensure the best care.
myTomorrows, a company with a missions to connect patients, physicians and biopharma companies to reach solutions that benefit everyone, have launched a clinical trial database search tool to help patients.
The tool, TrialSearch AI, is a physician-focused, pre-screening clinical trial search tool that uses AI technology to assist physicians in identifying clinical trials or expanded access programmes that could be beneficial for their patients.
In normal practice, a physician will go through a patients entire medical background, and compare this to a myriad of specific clinical trial criteria – a time consuming activity. TrialSearch AI provides a much faster, more efficient way of doing this by running a side by side comparison of patient medical history and publicly available clinical trial eligibility criteria or expanded access programme criteria from programmes around the world. Once the tool has run the search, it requests that the physician complete some further manual checks, and whether a pre-approval option is applicable for particular patients.
The tool can reduce the time physicians spend manually searching for trials by up to 90%, whilst still maintaining the layer of human decision making to give patients the best opportunity for personalised care.
The tools should be able to help patients with unmet needs and be especially useful for those with rare diseases.
“Our team of researchers and developers designed TrialSearch AI to bring greater speed, transparency, and accuracy to the complex, time-consuming task of manually searching for clinical trials. As a physician who cared for patients diagnosed with cancer, I know first-hand the importance of providing actionable information that can help physicians, patients, and caregivers discover and access potentially life-saving treatments,” commented Michel van Harten, CEO of myTomorrows.
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News CPHI Pharma Awards 2024: Meet the winners from the CPHI Celebration
This year we had a lot to celebrate, the 35th Anniversary of CPHI, and our esteemed award winners, of which we included two additional categories this year, the Future Leader award, and Woman of the Year award. -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance